Search
Hemab Therapeutics Holdings Ord Shs (Proposed)
COAGAdd to Watchlist
40.860USD
+1.480+3.76%
Close 11-13 16:00（ET）
1.91BMarket Cap
0.00P/E TTM
COAG Analyst Recommendation Trends
In the current month, COAG has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. COAG average Analyst price target in the last month is 62.667.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
1
0
0
0
3
3
3
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
3
0
0
0
Financial Forecasting
Based on analysts' estimates, COAG EPS is projected to reach -0.601 in FY2026Q4, following reported EPS of -0.585 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
--
-0.74
-0.52
-0.60
-0.59
Actual
-0.51
-0.52
-0.58
--
--
Surprise
--
+30.22%
-11.55%
--
--
FAQs
How have Hemab Therapeutics Holdings Ord Shs (Proposed)COAG's recent earnings per share performed?
The market expectation was USD -0.58, while Hemab Therapeutics Holdings Ord Shs (Proposed)COAG's earnings per share (EPS) for the previous quarter was USD -0.52. EPS for the next quarter is expected at USD -0.59.
What is the analyst rating for Hemab Therapeutics Holdings Ord Shs (Proposed)?
Based on the ratings of Hemab Therapeutics Holdings Ord Shs (Proposed)'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.